News
ALGS
5.59
+1.45%
0.08
Piper Sandler Sticks to Their Buy Rating for Aligos Therapeutics (ALGS)
TipRanks · 2d ago
Aligos Therapeutics reports Q2 EPS (14c), consensus ($1.38)
TipRanks · 3d ago
*Aligos Therapeutics 2Q Loss $1.5M >ALGS
Dow Jones · 3d ago
Press Release: Aligos Therapeutics Reports Recent -2-
Dow Jones · 3d ago
Weekly Report: what happened at ALGS last week (0727-0731)?
Weekly Report · 6d ago
Weekly Report: what happened at ALGS last week (0720-0724)?
Weekly Report · 07/27 09:34
Weekly Report: what happened at ALGS last week (0713-0717)?
Weekly Report · 07/20 09:32
Analyst Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target Amid Strengthened HBV Trial Outlook
TipRanks · 07/14 10:15
Aligos Completes Enrollment In Phase 2 Trial Of Pevifoscorvir Sodium For HBV; Stock Down
NASDAQ · 07/13 14:47
Aligos Therapeutics completes enrollment in B-SUPREME study
TipRanks · 07/13 12:06
Aligos Therapeutics Completes Enrollment Of HBeAg+ Patients In Its Phase 2 B-SUPREME Trial Of Pevifoscorvir Sodium To Treat Chronic Hepatitis B Virus Infection
Benzinga · 07/13 12:01
Weekly Report: what happened at ALGS last week (0706-0710)?
Weekly Report · 07/13 09:33
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
Barchart · 07/13 07:00
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX)
TipRanks · 07/07 11:50
Aligos Therapeutics Stock Is Trending Overnight: Here's What's Going On With ALGS Stock
Benzinga · 07/07 06:01
Aligos Secures $25M Upfront In Greater China HBV Deal; Stock Up
NASDAQ · 07/07 05:00
Closing Bell Movers: Crinetics doubles on Vertex buyout
TipRanks · 07/06 23:35
Aligos Therapeutics' Shares Rally Following $25M Payment From Xiamen Amoytop Biotech
Dow Jones · 07/06 21:53
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 07/06 21:05
Aligos Therapeutics receives $25M upfront for pevifoscorvir sodium license deal
TipRanks · 07/06 20:10
More
Webull provides a variety of real-time ALGS stock news. You can receive the latest news about Aligos Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.